Paper32089923
Male Breast Cancer: Reevaluate Our Opinion.
Kale S and 3 others. Case Rep Oncol Med, 2020. Cited by 0 papers, by iCite.
Cite this record
ConductScience Library. Male Breast Cancer: Reevaluate Our Opinion. Papers, record 32089923. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/32089923
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
Topics0
NLM's MeSH indexing of the paper, its major topics first.
None in this release.
References9
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 25543329 | Breast Cancer: Epidemiology and Etiology. | Cell Biochem Biophys | 2015 | https://conductscience.org/library/papers/25543329 | PubMed |
| 2 | 28331724 | Male Breast Cancer. | J Breast Health | 2016 | https://conductscience.org/library/papers/28331724 | PubMed |
| 3 | 30620402 | Cancer statistics, 2019. | CA Cancer J Clin | 2019 | https://conductscience.org/library/papers/30620402 | PubMed |
| 4 | 24367166 | HER2-positive male breast cancer: an update. | Breast Cancer (Dove Med Press) | 2010 | https://conductscience.org/library/papers/24367166 | PubMed |
| 5 | 27493913 | The importance of BRCA1 and BRCA2 genes mutations in breast cancer development. | Med J Islam Repub Iran | 2016 | https://conductscience.org/library/papers/27493913 | PubMed |
| 6 | 9605801 | Tamoxifen for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group. | Lancet | 1998 | https://conductscience.org/library/papers/9605801 | PubMed |
| 7 | 19184227 | Men with breast cancer have same disease-specific and event-free survival as women. | Ann Surg Oncol | 2009 | https://conductscience.org/library/papers/19184227 | PubMed |
| 8 | 1345950 | Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy. 133 randomised trials involving 31,000 recurrences and 24,000 deaths among 75,000 women. Early Breast Cancer Trialists' Collaborative Group. | Lancet | 1992 | https://conductscience.org/library/papers/1345950 | PubMed |
| 9 | 26994487 | Male breast cancer, clinical presentation, diagnosis and treatment: Twenty years of experience in our Breast Unit. | Int J Surg Case Rep | 2016 | https://conductscience.org/library/papers/26994487 | PubMed |
Genes5
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes | Source |
|---|---|---|---|---|
| BRCA1 | 672 | PubTator's text mining | https://conductscience.org/library/genes/672 | NCBI Gene |
| BRCA2 | 675 | PubTator's text mining | https://conductscience.org/library/genes/675 | NCBI Gene |
| EREG | 2069 | PubTator's text mining | https://conductscience.org/library/genes/2069 | NCBI Gene |
| ESR1 | 2099 | PubTator's text mining | https://conductscience.org/library/genes/2099 | NCBI Gene |
| PGR | 5241 | PubTator's text mining | https://conductscience.org/library/genes/5241 | NCBI Gene |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Cited by
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/32089923
GET https://conductscience.org/api/papers/v1/32089923/authors